Zheng YL, Li L, Jia YX, Zhang BZ, Li JC, Zhu YH, Li MQ, He JZ, Zeng TT, Ban XJ, Yuan YF, Li Y, Guan XY. ✉ Corresponding authors: Xin-Yuan Guan or Yan Li, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510062, China. *These authors contributed equally to this work. Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China Vascular Biology Research Institute, Guangdong Pharmaceutical University, Guangzhou 510006, Chinaĥ.

The People's Hospital of Baoan Shenzhen, The Affiliated Baoan Hospital of Southern Medical University, Shenzhen 518101, ChinaĤ. Department of Clinical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Chinaģ.

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510062, ChinaĢ. Yin-Li Zheng 1*, Lei Li 1*, Yong-Xun Jia 2, Bao-Zhu Zhang 1,3, Jiang-Chao Li 4, Ying-Hui Zhu 1, Meng-Qing Li 1, Jiao-Zi He 5, Ting-Ting Zeng 1, Xiao-Jiao Ban 1, Yun-Fei Yuan 1, Yan Li 1, Xin-Yuan Guan 1,5ġ.

Research Paper LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway

Solid converter pdf v2 2.158